Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25465514 | 0.81 | CYP1A2 (0.45) | KMT2ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL21177423 | 0.78 | KDM4E (0.45) | KMT2ASMN1; SMN2ADORA2AKDM4EALDH1A1 | |
| SCHEMBL28790800 | 0.77 | PDE4A (0.43) | KMT2ASMN1; SMN2KDM4EALDH1A1TP53 | |
| SCHEMBL9679763 | 0.76 | ADORA3 (0.47) | KMT2AADORA2AADORA3ALDH1A1 | |
| SCHEMBL31001796 | 0.75 | KDM4E (0.48) | KMT2ASMN1; SMN2ADORA2AADORA3KDM4E | |
| SCHEMBL20064712 | 0.74 | GAA (0.48) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL3607532 | 0.74 | ADORA2A (0.49) | KMT2ASMN1; SMN2ADORA2AADORA3KDM4E | |
| SCHEMBL21177165 | 0.73 | KDM4E (0.46) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL5066763 | 0.73 | POLB (0.45) | KMT2ASMN1; SMN2ADORA3KDM4EALDH1A1 | |
| SCHEMBL1298563 | 0.73 | MAPK1 (0.57) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | KMT2A 1239/4885SMN1; SMN2 4317/4885ADORA2A 2814/4885 |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | PI4K2A, PI4K2B, PI4KA | KMT2A 1679/4885SMN1; SMN2 4271/4885ADORA2A 981/4885 |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | PI4KB, PI4K2B, PI4K2A | KMT2A 1237/4885SMN1; SMN2 4375/4885ADORA2A 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.